Valuation: Insulet Corporation

Market Cap 11.55B 10B 9.32B 8.58B 16.19B 1,099B 16.38B 110B 42.96B 550B 43.39B 42.44B 1,822B P/E 2026 *
26.4x
P/E 2027 * 20.9x
Enterprise Value 11.62B 10.06B 9.38B 8.63B 16.29B 1,106B 16.47B 110B 43.22B 553B 43.66B 42.7B 1,833B EV / Sales 2026 *
3.5x
EV / Sales 2027 * 2.86x
Free-Float
97.63%
Yield 2026 *
-
Yield 2027 * -
1 day-0.09%
1 week-20.43%
Current month-19.41%
1 month-18.98%
3 months-22.25%
6 months-46.96%
Current year-53.12%
1 week 126.4
Extreme 126.4
172.1
1 month 126.4
Extreme 126.4
172.92
Current year 126.4
Extreme 126.4
299.8
1 year 126.4
Extreme 126.4
354.88
3 years 125.82
Extreme 125.82
354.88
5 years 125.82
Extreme 125.82
354.88
10 years 30.69
Extreme 30.69
354.88
Manager TitleAgeSince
Chief Executive Officer 55 28/04/2025
Director of Finance/CFO 53 30/09/2025
Compliance Officer 50 01/12/2022
Director TitleAgeSince
Chairman 61 01/01/2019
Director/Board Member 61 27/07/2015
Director/Board Member 59 10/08/2017
Date Insider Type Main position Quantity % Market Cap.
7/1/26 A Free

Director

1,355 0.0019%
7/1/26 A Other

Director

0 0%
6/30/26 A Free

Director

151 0.0002%
Change 5-day change 1-year change 3-year change Capi.($)
-20.12%-20.43%-53.69%-49.36% 11.55B
+0.24%-1.45%-18.64%-1.80% 182B
-0.24%-1.02%-4.07%+2.32% 110B
+3.57%-0.74%+8.03%+71.16% 59.59B
-0.10%+9.35%+43.37%+59.19% 55.04B
+0.32%+2.60%-4.61%-36.98% 46.87B
-12.79%-9.49% - - 35.55B
-4.92%+10.43%+8.41%-31.31% 32.81B
+0.65%+4.16%+47.25%-6.41% 24.54B
-0.06%+1.03%+1.87%+2.96% 22.69B
Average -1.34%+3.47%+3.10%+1.09% 58.15B
Weighted average by Cap. -0.62%+1.51%-0.63%+7.34%

Financials

2026 *2027 *
Net sales 3.32B 2.87B 2.68B 2.46B 4.65B 316B 4.7B 31.47B 12.34B 158B 12.47B 12.19B 523B 3.92B 3.39B 3.17B 2.91B 5.5B 373B 5.56B 37.19B 14.58B 187B 14.73B 14.41B 619B
Net income 427M 369M 344M 317M 598M 40.57B 605M 4.04B 1.59B 20.29B 1.6B 1.57B 67.27B 565M 489M 456M 420M 792M 53.74B 801M 5.36B 2.1B 26.88B 2.12B 2.08B 89.11B
Net Debt 69.76M 60.38M 56.29M 51.8M 97.74M 6.63B 98.86M 661M 259M 3.32B 262M 256M 11B -340M -294M -274M -252M -476M -32.34B -482M -3.22B -1.26B -16.17B -1.28B -1.25B -53.61B
Logo Insulet Corporation
Insulet Corporation specializes in the design, manufacture and marketing of medical devices intended to improve the lives of people with insulin-dependent diabetes. In addition, the group offers non-insulin subcutaneous drug delivery systems used in several therapeutic areas. Net sales break down by family of products as follows: - Insulin pump therapy systems (98.7%): continuous insulin management and delivery systems (Omnipod® and Omnipod DASH® brands) and automated insulin administration systems (Omnipod® 5 brand); - non-insulin drug administration systems (1.3%): in particular pre-filled syringes for the Neulasta® Onpro® kit (intended for the treatment of neutropenia in patients treated with chemotherapy). At the end of 2025, the group had 2 production sites located in the United States and in China. The United States account for 72.2% of net sales.
Employees
5,400
Date Price Change Volume
05/08/26 $133.26 -20.12% 7,143,932
04/08/26 $166.82 -1.70% 1,749,128
03/08/26 $169.70 +2.63% 1,408,011
31/07/26 $165.35 -0.20% 1,314,052
30/07/26 $165.68 -2.90% 1,215,698
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
25
Last Close Price
166.82USD
Average target price
233.46USD
Spread / Average Target
+39.95%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PODD Stock